Litcius/Paper detail

Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial

Bradley J. Monk, Takafumi Toita, Xiaohua Wu, Juan Carlos Vázquez Limón, R. Tarnawski, Masaki Mandai, Ronnie Shapira‐Frommer, Umesh Mahantshetty, Maria Del Pilar Estevez-Diz, Qi Zhou, Sewanti Limaye, Francisco Javier Ramírez Godinez, Christina Oppermann Kussler, Szilvia Varga, Natalia Valdiviezo, Daisuke Aoki, Manuel Leiva, Jung‐Yun Lee, Raymond Sulay, Yulia Kreynina, Wen‐Fang Cheng, Felipe Rey, Yi Rong, Guihao Ke, Sophie Wildsmith, Andrew R. Lloyd, Hannah Dry, Ana T. Nunes, Jyoti Mayadev

2023The Lancet Oncology204 citationsDOI

Topics & Concepts

DurvalumabMedicinePlaceboChemoradiotherapyCervical cancerDouble blindOncologyInternal medicineCancerPathologyNivolumabAlternative medicineImmunotherapyEndometrial and Cervical Cancer TreatmentsCancer Immunotherapy and BiomarkersColorectal and Anal Carcinomas